Evidence map›Paper›PMID 37199719›Full record

ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2023

Changes in Lung Volumes with Spirometric Disease Progression in COPD.

Mehrdad Arjomandi, Siyang Zeng, Jianhong Chen, Surya P Bhatt, Fereidoun Abtin, Igor Barjaktarevic, R Graham Barr, Eugene R Bleecker, Russell G Buhr, Gerard J Criner and 23 more

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969344 (Subpopulations and Intermediate Outcome Measures in COPD Study), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01969344 active not recruitingnot on this map

Subpopulations and Intermediate Outcome Measures in COPD Study

TypeobservationalSponsorUniversity of North Carolina, Chapel HillRan2010 to 2031Enrolled2,981ConditionsCOPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Definitions of early COPD and predictors for disease progression: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Association of Ground-Glass Opacities with Systemic Inflammation and Progression of Emphysema.American journal of respiratory and critical care medicine · 2024
    Article
  8. The Puzzle of Marijuana Use and Forced Vital Capacity.Annals of the American Thoracic Society · 2024
    Review
  9. Quantitative Analysis for Lung Disease on Thin-Section CT.Diagnostics (Basel, Switzerland) · 2023
    Review
  10. A STAR Is Born: A New Approach to Assessing Chronic Obstructive Pulmonary Disease Severity.American journal of respiratory and critical care medicine · 2023
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 1 country.

Mehrdad ArjomandiSan Francisco Veterans Affairs Healthcare System, San Francisco, California, United States.
Siyang ZengSan Francisco Veterans Affairs Healthcare System, San Francisco, California, United States.
Jianhong ChenSan Francisco Veterans Affairs Healthcare System, San Francisco, California, United States.
Surya P BhattUniversity of Alabama at Birmingham, Birmingham, Alabama, United States.
Fereidoun AbtinDepartment of Medicine, University of California, Los Angeles, California, United States.
Igor BarjaktarevicDepartment of Medicine, University of California, Los Angeles, California, United States.
R Graham BarrColumbia-Presbyterian Medical Center, New York, New York, United States.
Eugene R BleeckerUniversity of Arizona, College of Medicine, Tucson, Arizona, United States.
Russell G BuhrDepartment of Medicine, University of California, Los Angeles, California, United States.
Gerard J CrinerTemple University, Philadelphia, Pennsylvania, United States.
Alejandro P ComellasUniversity of Iowa, Iowa City, Iowa, United States.
David J CouperUniversity of North Carolina, Chapel Hill, North Carolina, United States.
Jeffrey L CurtisDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States.
Mark T DransfieldUniversity of Alabama at Birmingham, Birmingham, Alabama, United States.
Spyridon FortisUniversity of Iowa, Iowa City, Iowa, United States.
MeiLan K HanDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States.
Nadia N HanselJohns Hopkins Medical Institute, Baltimore, United States.
Eric A HoffmanUniversity of Iowa, Iowa City, Iowa, United States.
John E HokansonDepartment of Epidemiology, School of Public Health, University of Colorado, United States.
Robert J KanerWeill Cornell Medical Center, New York, New York, United States.
Richard E KannerUniversity of Utah, Salt Lake City, Utah, United States.
Jerry A KrishnanUniversity of Illinois at Chicago, Chicago, Illinois, United States.
Wassim W LabakiDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States.
David A LynchDepartment of Radiology, National Jewish Health Systems, Denver, Colorado, United States.
Victor E OrtegaMayo Clinic, Scottsdale, Arizona, United States.
Stephen P PetersWake Forest School of Medicine, Winston-Salem, North Carolina, United States.
Prescott G WoodruffDepartment of Medicine, University of California, San Francisco, California, United States.
Christopher B CooperDepartment of Medicine, University of California, Los Angeles, California, United States.
Russell P BowlerDepartment of Medicine, National Jewish Health Systems, Denver, Colorado, United States.
Robert PaineUniversity of Utah, Salt Lake City, Utah, United States.
Stephen I RennardUniversity of Nebraska Medical Center, Omaha, Nebraska, United States.
Donald P TashkinColumbia-Presbyterian Medical Center, New York, New York, United States.
and the COPDGene and SPIROMICS Investigators
University of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of Iowa · USNewYork–Presbyterian Hospital · USUniversity of Alabama at Birmingham · USUniversity of Colorado Denver · USUniversity of Michigan–Ann Arbor · USUniversity of North Carolina at Chapel Hill · USColorado School of Public Health · USCornell University · USJohns Hopkins University · USMayo Clinic in Arizona · USNational Jewish Health · USSan Francisco VA Medical Center · USTemple University · USUniversity of Arizona · USUniversity of Illinois Chicago · USUniversity of Nebraska Medical Center · USUniversity of Utah · USWake Forest University · US

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Brandi Janssen · 1990 to 2026
$40.5M
Metabolomic signatures of empysema and COPD progression in the COPDGene cohortR01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2012 to 2016
$31.1M
Vector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Alejandro Antonio Pezzulo · 1998 to 2026
$30.5M
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
University of Washington Biomedical Informatics and Data Science Research Training ProgramT15LM007442 · NLM · UNIVERSITY OF WASHINGTON · PI JOHN H. GENNARI, Andrea L. Hartzler · 2002 to 2026
$19.6M
(2 of 2) Genetic Epidemiology of COPDR01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2012 to 2016
$18.9M
The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
SPIROMICS GIC SupportU24HL141762 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J, O'NEAL, WANDA K · 2018 to 2022
$7.2M
Mentoring Research in Precision Medicine for Lung DiseaseK24HL137013 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2017 to 2026
$1.2M
NCATS NIH HHS KL2 TR001882NHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900017CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS K24 HL137013NHLBI NIH HHS R01 HL089856NHLBI NIH HHS R01 HL089897NHLBI NIH HHS U01 HL137880NHLBI NIH HHS U24 HL141762NIDDK NIH HHS P30 DK054759NIEHS NIH HHS P30 ES005605NLM NIH HHS T15 LM007442NLM NIH HHS T15LM007442VA CXV-00125
6 · The paper itself

Abstract

Background: Abnormal lung volumes representing air trapping identify the subset of smokers with preserved spirometry who develop spirometric chronic obstructive pulmonary disease (COPD) and adverse outcomes. However, how lung volumes evolve in early COPD as airflow obstruction develops remains unclear. Methods: To establish how lung volumes change with the development of spirometric COPD, we examined lung volumes from the pulmonary function data (seated posture) available in the U.S. Department of Veterans Affairs electronic health records (n=71,356) and lung volumes measured by computed tomography (supine posture) available from the COPD Genetic Epidemiology (COPDGene Results: Lung volumes from all 3 cohorts showed similar patterns of distributions and longitudinal changes with worsening airflow obstruction. The distributions for total lung capacity (TLC), vital capacity (VC), and inspiratory capacity (IC) and their patterns of change were nonlinear and included different phases. When stratified by airflow obstruction using Global initiative for chronic Obstructive Lung Disease (GOLD) stages, patients with GOLD 1 (mild) COPD had larger lung volumes (TLC, VC, IC) compared to patients with GOLD 0 (smokers with preserved spirometry) or GOLD 2 (moderate) disease. In longitudinal follow-up of baseline GOLD 0 patients who progressed to spirometric COPD, those with an initially higher TLC and VC developed mild obstruction (GOLD 1) while those with an initially lower TLC and VC developed moderate obstruction (GOLD 2). Conclusions: In COPD, TLC, and VC have biphasic distributions, change in nonlinear fashions as obstruction worsens, and could differentiate those GOLD 0 patients at risk for more rapid spirometric disease progression.

Indexed as

air trappingcomputed tomographyCOPDearly diseaselung volumes

Identifiers

PMID37199719
PMCPMC10484496
OpenAlexW4377008071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.